DE69332519T2 - Defekte verpackende nicht-oncoviren vektoren aus mpmv - Google Patents

Defekte verpackende nicht-oncoviren vektoren aus mpmv

Info

Publication number
DE69332519T2
DE69332519T2 DE69332519T DE69332519T DE69332519T2 DE 69332519 T2 DE69332519 T2 DE 69332519T2 DE 69332519 T DE69332519 T DE 69332519T DE 69332519 T DE69332519 T DE 69332519T DE 69332519 T2 DE69332519 T2 DE 69332519T2
Authority
DE
Germany
Prior art keywords
vectors
packaging
lentivirus
mpmv
oncovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69332519T
Other languages
English (en)
Other versions
DE69332519D1 (de
Inventor
Michael Lever
Eric Hunter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenix Ltd
Original Assignee
Syngenix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929204350A external-priority patent/GB9204350D0/en
Priority claimed from GB929208489A external-priority patent/GB9208489D0/en
Application filed by Syngenix Ltd filed Critical Syngenix Ltd
Publication of DE69332519D1 publication Critical patent/DE69332519D1/de
Application granted granted Critical
Publication of DE69332519T2 publication Critical patent/DE69332519T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Packages (AREA)
  • Packging For Living Organisms, Food Or Medicinal Products That Are Sensitive To Environmental Conditiond (AREA)
  • Auxiliary Devices For And Details Of Packaging Control (AREA)
  • Supplying Of Containers To The Packaging Station (AREA)
DE69332519T 1992-02-28 1993-03-01 Defekte verpackende nicht-oncoviren vektoren aus mpmv Expired - Fee Related DE69332519T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929204350A GB9204350D0 (en) 1992-02-28 1992-02-28 Dtv agents
GB929208489A GB9208489D0 (en) 1992-04-16 1992-04-16 Ctv agents
GB929219935A GB9219935D0 (en) 1992-04-16 1992-09-21 Ctv agents
PCT/GB1993/000417 WO1993017118A2 (en) 1992-02-28 1993-03-01 Defective packaging non-oncoviral vectors based on mpmv and hiv

Publications (2)

Publication Number Publication Date
DE69332519D1 DE69332519D1 (de) 2003-01-09
DE69332519T2 true DE69332519T2 (de) 2003-07-17

Family

ID=27266069

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69332519T Expired - Fee Related DE69332519T2 (de) 1992-02-28 1993-03-01 Defekte verpackende nicht-oncoviren vektoren aus mpmv

Country Status (11)

Country Link
US (2) US5747307A (de)
EP (2) EP1262554A3 (de)
JP (2) JP3765103B2 (de)
AT (1) ATE228569T1 (de)
AU (1) AU671101B2 (de)
CA (2) CA2557882C (de)
DE (1) DE69332519T2 (de)
DK (1) DK0630409T3 (de)
ES (1) ES2187504T3 (de)
PT (1) PT630409E (de)
WO (1) WO1993017118A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2269175A (en) * 1992-07-31 1994-02-02 Imperial College Retroviral vectors
WO1995025806A2 (en) * 1994-03-24 1995-09-28 Syngenix Limited Packaging-deficient lentiviruses
US5714353A (en) * 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
GB9510272D0 (en) * 1995-05-22 1995-07-19 Isis Innovation Retroviral vectors
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
FR2747046B1 (fr) * 1996-04-05 1998-06-19 Univ Paris Curie Nouveaux vaccins issus de plasmovirus
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
US6797512B1 (en) 1998-11-13 2004-09-28 Cell Genesys, Inc. Selection system for generating efficient packaging cells for lentiviral vectors
ATE366740T1 (de) * 1998-11-13 2007-08-15 Cell Genesys Inc Auswahlverfahren zur erzeugung effizienter pack- zellen für lentivirale vektoren
US6790657B1 (en) * 1999-01-07 2004-09-14 The United States Of America As Represented By The Department Of Health And Human Services Lentivirus vector system
IL146144A0 (en) * 1999-04-29 2002-07-25 Cell Genesys Inc Method and means for producing high titer, safe, recombinant lentivirus vectors
WO2000072886A1 (en) 1999-05-26 2000-12-07 Dana-Farber Cancer Institute, Inc. Episomally replicating lentiviral vectors
WO2002060490A1 (en) * 2001-01-31 2002-08-08 Duke University Retroviral vector
GB0108065D0 (en) * 2001-03-30 2001-05-23 Syngenix Ltd Viral vectors
US6808905B2 (en) 2001-05-14 2004-10-26 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
ATE535260T1 (de) * 2001-06-29 2011-12-15 Sloan Kettering Inst Cancer Vektor kodierend humanes globin-gen und seine verwendung bei der behandlung von hämoglobinopathien

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604114A (en) * 1986-05-20 1997-02-18 Dana-Farber Cancer Institute Cis-acting repression sequences, cis-acting antirepression sequences, vectors, methods of preparation and use
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
EP0496794A1 (de) * 1989-10-16 1992-08-05 Whitehead Institute For Biomedical Research Nichtinfektiöse partikeln von hiv-1 und verwendungen davon
US5861282A (en) * 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
EP0536234A4 (en) * 1990-06-20 1993-09-15 Dana Farber Cancer Institute Vectors containing hiv packaging sequences, packaging defective hiv vectors, and uses thereof
US6174666B1 (en) * 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA

Also Published As

Publication number Publication date
ATE228569T1 (de) 2002-12-15
EP1262554A3 (de) 2007-08-29
AU3639493A (en) 1993-09-13
DE69332519D1 (de) 2003-01-09
WO1993017118A3 (en) 1993-10-14
EP1262554A2 (de) 2002-12-04
EP0630409B1 (de) 2002-11-27
CA2557882C (en) 2010-05-18
AU671101B2 (en) 1996-08-15
JP3779966B2 (ja) 2006-05-31
US5747307A (en) 1998-05-05
EP0630409A1 (de) 1994-12-28
US6294165B1 (en) 2001-09-25
JPH07504322A (ja) 1995-05-18
CA2557882A1 (en) 1993-09-02
WO1993017118A2 (en) 1993-09-02
ES2187504T3 (es) 2003-06-16
JP2004000280A (ja) 2004-01-08
CA2117607A1 (en) 1993-09-02
JP3765103B2 (ja) 2006-04-12
DK0630409T3 (da) 2003-03-24
PT630409E (pt) 2003-04-30

Similar Documents

Publication Publication Date Title
ATE228569T1 (de) Defekte verpackende nicht-oncoviren vektoren aus mpmv
DE3381568D1 (de) Verfahren zum einbringen von expressionsfaehigen genen in pflanzenzellgenome und hybride ti plasmidvektoren enthaltende agrobacterium-staemme verwendbar in diesem verfahren.
AU6438086A (en) Novel plant plasmid vector
EP0459643A3 (en) A recombinant promoter for gene expression in monocotyledonous plants
IL60186A0 (en) Dna transfer vector,microorganisms transformed thereby and a method for cloning a dioxynucleotide sequence
ATE248915T1 (de) Für oligosaccharidetransporter kodierende dna sequenzen
ATE386120T1 (de) Salmonella genom nukleinsäure, ihre verwendung, besonders bei der in vitro diagnose der anwesenheit von bakterien der gattung salmonella in lebensmitteln
EP0769553A4 (de) Dna-fragment, rekombinanter vektor, der es enthält, und verfahren zur expression von fremdgenen mit seiner nutzung
HU9500030D0 (en) Dna sequences for an amino acid transporter, plasmids, bacteria, yeasts and plants containing a transporter and their use
DE3485814D1 (de) Von t-dns abgeleitete vector.
ZA857862B (en) Cloning or expression vectors containing the avian erythroblastosis virus genome and cells transfected by these vectors
ATE173762T1 (de) Klonierung der n-methylhydantoinase
ATE199397T1 (de) Multiple virus-resistenz aufweisende transgene pflanzen und verfahren zu ihrer herstellung
GR78104B (de)
DE59611131D1 (de) Acarbose-Biosynthesegene aus Actinoplanes sp., Verfahren zu ihrer Isolierung sowie ihrer Verwendung
WO1999060140A3 (en) Geminivirus inducible promoter sequences and the uses thereof
ATE173764T1 (de) Lineare plasmide von pichia pastoris und fragmente davon
HK1084148A1 (en) Mn gene and protein
TH7509A (th) กระบวนการที่ใช้ในการรวมยีนที่เลือกสรรแล้วเข้าเป็นหน่วยเดียวกันกับโครโมโซมของแบคทีเรีย และแบคทีเรียที่ได้จากกระบวนการดังกล่าว
TH7509EX (th) กระบวนการที่ใช้ในการรวมยีนที่เลือกสรรแล้วเข้าเป็นหน่วยเดียวกันกับโครโมโซมของแบคทีเรีย และแบคทีเรียที่ได้จากกระบวนการดังกล่าว
HUP9902608A2 (hu) Ózonindukált génexpresszió növényekben
HUT77446A (hu) Hímfertilitást közvetítő nukleotidszekvenciák és eljárások azok alkalmazására

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee